PARTNER EVENT: Swiss Nordic Bio 2022
Connecting Healthcare Innovations, Investors and Industry
Swiss Nordic Bio at a glance
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 15 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organised by the Nordic countries in cooperation with Swiss partners.
Focus
The conference has a broad focus within biotech and pharma (drug development, drug delivery, bio materials, medical device, diagnostics, contract manufacturing, CRO, etc.) and gathers small, early stage companies as well as global, commercial corporations.
The conference is open for biotech and pharma companies as well as investors within the life science industry.
Agenda
What is new?
• Swiss Nordic Bio 2022 is back to physical format
• On the day of the conference, pre-booked 1-on-1 meetings meetings will be held face-to-face and on site
• Together with Vator Securities we continue to make Swiss Nordic Bio a leading small & midcap healthcare conference
Why attend?
• Meet the most promising healthcare companies from the Nordics & Switzerland
• Up to 75 investors participating
• Pitching will be possible during conference on site
• Exclusive conference with max 200 participants admitted
• 1 day event with +400 1-on-1 meetings
Already 80+ confirmed participants include
• Investors: Earlybird, Veraison Capital, Wille Finance, Apus Capital, Hadean Ventures, IPF Partners, Eiffel Investment Group and more
• SMEs & publicly listed companies: Scandion Oncology, Oasmia, Kancera, Sprint Bioscience, Magle Chemoswed and more
• For the latest list see here
Who attends?
• Leading listed healthcare companies
• Cutting edge private healthcare companies
• Public equity investors focusing on SME’s
• Venture capital and family offices
• Pharma & medtech innovation scouts
• For the latest list of registered participants see here
Organised by
